Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk shares have fallen more than 66% from their 2024 high as Eli Lilly took the lead in GLP-1 weight-loss drugs, leaving the company in a competitive turnaround phase. The stock trades at 4.0x sales, 11.6x earnings and 6.1x book value, materially below its historical averages and below the drug-industry average P/E of 26.5x; it also offers a 3.7% dividend yield with a payout ratio below 40%. Novo is pursuing a Wegovy pill and lower-priced, volume-driven GLP-1 strategy, but near-term revenue and earnings have weakened and the ability to regain market share remains uncertain.

Analysis

NVO’s apparent value is not a conventional mean-reversion setup: the market is discounting a durable reset in GLP-1 economics, not merely a temporary share loss. A volume-led strategy can stabilize prescription share but risks turning obesity care into a lower-price, higher-rebate category; the key variable is incremental gross profit per patient, not unit growth. If net price concessions outpace manufacturing-cost declines, NVO can grow treated patients while still face EPS estimate cuts and a structurally lower multiple.

LLY’s advantage is potentially self-reinforcing over the next 1-3 months: superior prescriber familiarity, payer formulary positioning, and scale can sustain premium net pricing while NVO absorbs the cost of defending access. The more important competitive read-through is whether oral GLP-1 expands the total treated population or cannibalizes injectables. Category expansion would favor both names, but injectable-to-oral substitution at lower net prices would be more damaging to NVO because its turnaround depends on mix and margin recovery.

The contrarian case is that NVO’s valuation already embeds an unusually pessimistic outcome and its legacy diabetes franchise plus capital returns limit downside if obesity pricing stabilizes. A credible inflection requires independently visible evidence: sequential improvement in net sales per prescription, stable gross margin, and management maintaining or raising FY EPS guidance. Absent those metrics, buying solely on trailing P/E risks a value trap; pharma multiples rarely rerate before estimate revisions stop falling.

Over 6-18 months, lower obesity-drug pricing could broaden reimbursement and increase utilization, benefiting distributors and pharmacy channels but pressuring both manufacturers’ returns on incremental capacity. Watch PBM formulary announcements and U.S. coverage expansion: these can move demand materially faster than clinical differentiation, while any safety signal, reimbursement restriction, or new efficacy data could rapidly reverse relative positioning.

Key Decisions for Investors

• Maintain LLY over NVO as the core relative-value expression for the next 1-3 months; use a long LLY / short NVO dollar-neutral pair only after confirming NVO consensus FY EPS revisions remain negative. Target relative upside from continued estimate dispersion; exit if NVO reports two consecutive quarters of improving revenue per prescription and gross-margin stabilization.
• Do not initiate an outright NVO value long before its next earnings update. Create a catalyst watch: buy NVO only if guidance is maintained or raised alongside sequential U.S. obesity net-sales acceleration; use a 10-12% downside stop from entry because another pricing-driven guidance cut would likely prevent multiple expansion.
• For long-only exposure, prefer staged NVO accumulation over 3-6 months rather than a full position today. The risk/reward improves materially if the forward earnings multiple remains depressed while dividend coverage and operating cash flow hold; reduce if payout coverage weakens or management signals additional broad-based price reductions.
• Monitor LLY valuation risk separately from operating momentum. If payer actions force category-wide net-price concessions, LLY’s premium multiple has more absolute downside than NVO; hedge a concentrated LLY long with short-dated downside protection around formulary and earnings catalysts rather than assuming share leadership insulates margins.